Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art

Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art Long recognized to confer an extremely poor prognosis, sarcomatoid dedifferentiation of renal cell carcinoma (sRCC) is a tumor phenotype that is finally beginning to be better understood on the molecular and genetic levels. With an overall incidence that ranges from 1 to 32% depending on associated RCC subtype, the survival of sarcomatoid RCC patients rarely exceeds 2 years. The main reasons for its poor outcome include its aggressive biology, its tendency to present at an advanced or metastatic stage at the time of diagnosis, its high rate of tumor recurrence after nephrectomy, and its limited response to systemic therapies. Molecular pathology studies suggest that sarcomatoid dedifferentiation originates from a focal epithelial–mesenchymal transition (EMT) arising in the carcinomatous component of the tumor. It is hoped that the growing understanding of the molecular biology of sRCC will soon make it possible to adapt treatments based on the identification of actionable tumor alterations. The deliberate inclusion of these patients in the multicenter clinical trials of immune, targeted and combination therapies is a necessary next step in pioneering future treatment strategies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png World Journal of Urology Springer Journals

Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art

Download PDF
9 pages

Loading next page...
 
/lp/springer_journal/epidemiology-biology-and-treatment-of-sarcomatoid-rcc-current-state-of-d68SIB7BoF
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Urology; Nephrology; Oncology
ISSN
0724-4983
eISSN
1433-8726
DOI
10.1007/s00345-018-2355-y
Publisher site
See Article on Publisher Site

Abstract

Long recognized to confer an extremely poor prognosis, sarcomatoid dedifferentiation of renal cell carcinoma (sRCC) is a tumor phenotype that is finally beginning to be better understood on the molecular and genetic levels. With an overall incidence that ranges from 1 to 32% depending on associated RCC subtype, the survival of sarcomatoid RCC patients rarely exceeds 2 years. The main reasons for its poor outcome include its aggressive biology, its tendency to present at an advanced or metastatic stage at the time of diagnosis, its high rate of tumor recurrence after nephrectomy, and its limited response to systemic therapies. Molecular pathology studies suggest that sarcomatoid dedifferentiation originates from a focal epithelial–mesenchymal transition (EMT) arising in the carcinomatous component of the tumor. It is hoped that the growing understanding of the molecular biology of sRCC will soon make it possible to adapt treatments based on the identification of actionable tumor alterations. The deliberate inclusion of these patients in the multicenter clinical trials of immune, targeted and combination therapies is a necessary next step in pioneering future treatment strategies.

Journal

World Journal of Urology – Springer Journals

Published: Jun 1, 2018

References

  • Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
    Ferlay, J; Steliarova-Foucher, E; Lortet-Tieulent, J
  • The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters
    Delahunt, B; Cheville, JC; Martignoni, G
  • Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    Golshayan, AR; George, S; Heng, DY
  • Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease
    Molina, AM; Tickoo, SK; Ishill, N
  • Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: comparison between the cytokine and targeted therapy eras
    Keskin, SK; Msaouel, P; Hess, KR
  • The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours
    Moch, H; Cubilla, AL; Humphrey, PA
  • Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma
    Mian, BM; Bhadkamkar, N; Slaton, JW
  • Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma
    Gu, L; Li, H; Wang, H
  • Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome
    Cheville, JC; Lohse, CM; Zincke, H
  • Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases
    Peralta-Venturina, M; Moch, H; Amin, M
  • Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases
    Amin, MB; Amin, MB; Tamboli, P
  • Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy
    Shuch, B; Said, J; LaRochelle, JC
  • Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma
    Shuch, B; Bratslavsky, G; Shih, J
  • A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study
    Capitanio, U; Cloutier, V; Zini, L
  • Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis
    Kim, HL; Belldegrun, AS; Freitas, DG
  • Sarcomatoid renal cell carcinoma and collecting duct carcinoma: discrimination from common renal cell carcinoma subtypes and benign RCC mimics on multiphasic MDCT
    Young, JR; Young, JA; Margolis, DJA
  • Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects
    Kuroda, N; Toi, M; Hiroi, M; Enzan, H
  • Low-grade spindle cell proliferation in clear cell renal cell carcinoma is unlikely to be an initial step in sarcomatoid differentiation
    Tanas Isikci, O; He, H; Grossmann, P
  • Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma
    Kwak, C; Park, YH; Jeong, CW
  • The basics of epithelial–mesenchymal transition
    Kalluri, R; Weinberg, RA
  • Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation
    Jones, TD; Eble, JN; Wang, M
  • Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: an intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity
    Sanfrancesco, JM; Eble, JN; Grignon, DJ
  • Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas
    Sircar, K; Yoo, S-Y; Majewski, T
  • Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
    Bi, M; Zhao, S; Said, JW
  • Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations
    Malouf, GG; Ali, SM; Wang, K
  • Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
    Gerlinger, M; Horswell, S; Larkin, J
  • Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape
    Wang, Z; Kim, TB; Peng, B
  • Sarcomatoid renal cell carcinoma: the apple doesn’t fall far from the tree
    Bergerot, P; Agarwal, N; Pal, SK; Jones, J
  • RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma
    Pal, SK; He, M; Tong, T
  • Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases
    Yu, W; Wang, Y; Jiang, Y
  • C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib
    Castillo, M; Petit, A; Mellado, B
  • Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors
    Visapää, H; Seligson, D; Huang, Y
  • Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically
    Nguyen, DP; Vilaseca, A; Vertosick, EA
  • Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma
    Trudeau, V; Larcher, A; Sun, M
  • Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Kyriakopoulos, CE; Chittoria, N; Choueiri, TK
  • High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features
    Achkar, T; Arjunan, A; Wang, H
  • Partial nephrectomy versus radical nephrectomy for clinical localised renal masses
    Kunath, F; Schmidt, S; Krabbe, L-M
  • The rationale and the role of lymph node dissection in renal cell carcinoma
    Capitanio, U; Leibovich, BC
  • Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
    Leibovich, BC; Blute, ML; Cheville, JC
  • Clinically non-metastatic renal cell carcinoma with sarcomatoid dedifferentiation: natural history and outcomes after surgical resection with curative intent
    Merrill, MM; Wood, CG; Tannir, NM
  • The role of metastasectomy in patients with renal cell carcinoma with sarcomatoid dedifferentiation: a matched controlled analysis
    Thomas, AZ; Adibi, M; Slack, RS
  • Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology—is up-front resection indicated and if not, is it avoidable?
    Shuch, B; Said, J; Rochelle, JC
  • Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma
    Michaelson, MD; McKay, RR; Werner, L
  • Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy
    Cangiano, T; Liao, J; Naitoh, J
  • Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study
    Eminaga, O; Akbarov, I; Wille, S; Engelmann, U
  • Outcomes following partial nephrectomy by tumor size
    Crispen, PL; Boorjian, SA; Lohse, CM
  • Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
    Haas, NB; Manola, J; Uzzo, RG
  • Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy
    Ravaud, A; Motzer, RJ; Pandha, HS
  • Updated European association of urology guidelines regarding adjuvant therapy for renal cell carcinoma
    Bex, A; Albiges, L; Ljungberg, B
  • Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results
    Motzer, RJ; Ravaud, A; Patard, J-J
  • Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study
    Patard, J-J; Kim, HL; Lam, JS
  • Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib
    Kunene, V; Miscoria, M; Pirrie, S
  • Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
    Voss, MH; Bastos, DA; Karlo, CA
  • A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802
    Haas, NB; Lin, X; Manola, J
  • Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers
    Escudier, B; Droz, JP; Rolland, F
  • Phase 2 trial of capecitabine, gemcitabine, and bevacizumab in sarcomatoid renal-cell carcinoma
    Maiti, A; Nemati-Shafaee, M; Msaouel, P
  • Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
    Dutcher, JP; Nanus, D
  • Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy?
    Culine, S; Bekradda, M; Terrier-Lacombe, MJ; Droz, JP
  • Rapid response to nivolumab in a patient with sarcomatoid transformation of chromophobe renal cell carcinoma
    Rouvinov, K; Osyntsov, L; Shaco-Levy, R
  • Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features
    Geynisman, DM
  • Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study
    McDermott, DF; Sosman, JA; Sznol, M
  • PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
    Joseph, RW; Millis, SZ; Carballido, EM